CN116419760A - 治疗酶融合蛋白在预防和治疗由法布里病引起或伴有法布里病的肾病中的用途 - Google Patents

治疗酶融合蛋白在预防和治疗由法布里病引起或伴有法布里病的肾病中的用途 Download PDF

Info

Publication number
CN116419760A
CN116419760A CN202180075093.2A CN202180075093A CN116419760A CN 116419760 A CN116419760 A CN 116419760A CN 202180075093 A CN202180075093 A CN 202180075093A CN 116419760 A CN116419760 A CN 116419760A
Authority
CN
China
Prior art keywords
pharmaceutical composition
fusion protein
enzyme
region
kidney
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180075093.2A
Other languages
English (en)
Chinese (zh)
Inventor
崔宰赫
金真英
C·R·朴
金尚允
金晶雅
D·S·张
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanmi Pharmaceutical Co Ltd
Original Assignee
Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of CN116419760A publication Critical patent/CN116419760A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
CN202180075093.2A 2020-11-13 2021-11-15 治疗酶融合蛋白在预防和治疗由法布里病引起或伴有法布里病的肾病中的用途 Pending CN116419760A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20200152247 2020-11-13
KR10-2020-0152247 2020-11-13
PCT/KR2021/016630 WO2022103221A1 (ko) 2020-11-13 2021-11-15 치료학적 효소 융합단백질의 파브리병에 기인하거나 동반되는 신장질환 예방 및 치료 용도

Publications (1)

Publication Number Publication Date
CN116419760A true CN116419760A (zh) 2023-07-11

Family

ID=81602509

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180075093.2A Pending CN116419760A (zh) 2020-11-13 2021-11-15 治疗酶融合蛋白在预防和治疗由法布里病引起或伴有法布里病的肾病中的用途

Country Status (12)

Country Link
US (1) US20230405093A1 (https=)
EP (1) EP4245311A4 (https=)
JP (1) JP2023549323A (https=)
KR (1) KR20220065719A (https=)
CN (1) CN116419760A (https=)
AU (1) AU2021378707A1 (https=)
CA (1) CA3196258A1 (https=)
CO (1) CO2023006437A2 (https=)
IL (1) IL302858A (https=)
MX (1) MX2023005580A (https=)
WO (1) WO2022103221A1 (https=)
ZA (1) ZA202304534B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202525329A (zh) * 2023-09-14 2025-07-01 南韓商綠十字股份有限公司 含有α－半乳糖苷酶Ａ融合蛋白的新穎冷凍乾燥製劑

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
HUE047173T2 (hu) * 2010-03-01 2020-04-28 Bayer Healthcare Llc Optimalizált monoklonális ellenanyagok szöveti faktor útvonal inhibitor (TFPI) ellen
WO2015009052A1 (ko) * 2013-07-16 2015-01-22 일동제약 주식회사 하이브리드 면역글로불린 fc와 효소의 융합단백질
AR107483A1 (es) * 2016-01-29 2018-05-02 Hanmi Pharm Ind Co Ltd Conjugado de enzimas terapéuticas
EP3565583A4 (en) * 2017-01-05 2020-12-02 Protalix Ltd. TREATMENT DIET FOR THE TREATMENT OF FABRY'S DISEASE USING STABILIZED ALPHA-GALACTOSIDASE
SG11202000115SA (en) * 2017-07-07 2020-02-27 Hanmi Pharmaceutical Co Ltd Novel therapeutic enzyme fusion protein and use thereof
FR3069340A1 (fr) * 2017-07-21 2019-01-25 Arkema France Procede de controle de l'orientation des nano-domaines d'un copolymere a blocs
MX2020006635A (es) * 2017-12-22 2020-12-10 Hanmi Pharm Ind Co Ltd Proteína de fusión enzimática terapéutica que tiene una nueva estructura y uso de la misma.

Also Published As

Publication number Publication date
EP4245311A1 (en) 2023-09-20
EP4245311A4 (en) 2024-10-30
JP2023549323A (ja) 2023-11-24
US20230405093A1 (en) 2023-12-21
IL302858A (en) 2023-07-01
MX2023005580A (es) 2023-05-29
CA3196258A1 (en) 2022-05-19
WO2022103221A1 (ko) 2022-05-19
AU2021378707A9 (en) 2024-07-11
ZA202304534B (en) 2024-10-30
KR20220065719A (ko) 2022-05-20
AU2021378707A1 (en) 2023-06-01
CO2023006437A2 (es) 2023-06-09

Similar Documents

Publication Publication Date Title
KR102712547B1 (ko) 신규한 구조를 갖는 치료학적 효소 융합단백질 및 이의 용도
US11260107B2 (en) Methods and compositions for treating ulcers
US20200255495A1 (en) Antagonists of actriib and uses for increasing red blood cell levels
AU2017201580B2 (en) Methods and compositions for treating ineffective erythropoiesis
RU2592670C2 (ru) Комбинированное применение ловушек gdf и активаторов рецепторов эритропоэтина для повышения содержания эритроцитов
US20200360475A1 (en) Methods for dosing an actriib antagonist and monitoring of treated patients
TWI748373B (zh) 使用gdf阱以增加紅血球水平
TW200906849A (en) Natriuretic fusion proteins
KR20170088927A (ko) 골수형성이상 증후군 및 철적혈모구 빈혈을 치료하기 위한 방법
EP2303917A2 (en) Antagonists of actriib and uses for increasing red blood cell levels
MX2012003005A (es) Antagonistas de actriib y dosificacion y usos de los mismos.
KR102569658B1 (ko) 컨쥬게이트 c1 에스테라제 억제제 및 그의 용도
CN116419760A (zh) 治疗酶融合蛋白在预防和治疗由法布里病引起或伴有法布里病的肾病中的用途
WO2023022968A2 (en) Compositions and methods for treating renal diseases or conditions
CN116419759A (zh) 治疗酶融合蛋白在预防和治疗由法布里病引起或伴有法布里病的神经病中的用途
KR20230134822A (ko) α-갈락토시다제 A의 융합단백질을 포함하는 액상 제제
EA051281B1 (ru) Применение слитого с терапевтическим ферментом белка для предупреждения и лечения почечного заболевания, вызванного или связанного с болезнью фабри
EA051314B1 (ru) Применение слитого с терапевтическим ферментом белка для предупреждения и лечения нейропатии, считающейся следствием болезни фабри или ассоциированной с болезнью фабри
OA19001A (en) Methods and compositions for treating ulcers

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination